Sanofi's Zerhouni at the EMA: More collaboration and fewer specialty medicines please
This article was originally published in Scrip
Executive Summary
The pooling of knowledge, collaboration rather than confrontation, stratified benefit-risk assessments, adaptive pathways, and the appliance of science to improve drug regulation. These are some of the key elements of Elias Zerhouni's vision of the future – or at least the future he'd like to see.